This work is licensed under the Creative Commons Attribution 4.0 International License.
Toyokuni S. Commentary on “mechanisms of asbestos-induced carcinogenesis” published in 2009. Nagoya J Med Sci 2023; 85: 13–5. doi: 10.18999/nagjms.85.1.13ToyokuniSCommentary on “mechanisms of asbestos-induced carcinogenesis” published in 200920238513510.18999/nagjms.85.1.13Open DOISearch in Google Scholar
Hajj GNM, Cavarson CH, Pinto CAL, Venturi G, Navarro JR, de Lima VCC.. Malignant pleural mesothelioma: an update. J Bras Pneumol 2021; 47: e20210129. doi: 10.36416/1806-3756/e20210129HajjGNMCavarsonCHPintoCALVenturiGNavarroJRde LimaVCCMalignant pleural mesothelioma: an update202147e2021012910.36416/1806-3756/e20210129Open DOISearch in Google Scholar
Brims F. Epidemiology and clinical aspects of malignant pleural mesothelioma. Cancers 2021; 13: 4194. doi: 10.3390/cancers13164194.BrimsFEpidemiology and clinical aspects of malignant pleural mesothelioma202113419410.3390/cancers13164194Open DOISearch in Google Scholar
Gaudino G, Xue J, Yang H. How asbestos and other fibers cause mesothelioma. Transl Lung Cancer Res 2020; 9(Suppl 1): S39–46. doi: 10.21037/tlcr.2020.02.01GaudinoGXueJYangHHow asbestos and other fibers cause mesothelioma20209Suppl 1S394610.21037/tlcr.2020.02.01Open DOISearch in Google Scholar
Tallet A, Nault JC, Renier A Hysi I, Galateau-Sallé F, A Cazes A, et al. Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma. Oncogene 2014; 33: 3748–52. doi: 10.1038/onc.2013.351TalletANaultJCRenierAHysiIGalateau-SalléFA CazesAOverexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma20143337485210.1038/onc.2013.351Open DOISearch in Google Scholar
Rossiello F, Jurk D, Passos JF, di Fagagna FA. Telomere dysfunction in ageing and age-related diseases. Nat Cell Biol 2022; 24: 135–47. doi: 10.1038/s41556-022-00842-xRossielloFJurkDPassosJFdi FagagnaFATelomere dysfunction in ageing and age-related diseases2022241354710.1038/s41556-022-00842-xOpen DOISearch in Google Scholar
Lin J, Epel E. Stress and telomere shortening: insights from cellular mechanisms. Ageing Res Rev 2022; 73: 101507. doi: 10.1016/j.arr.2021.101507LinJEpelEStress and telomere shortening: insights from cellular mechanisms20227310150710.1016/j.arr.2021.101507Open DOISearch in Google Scholar
Wadowski B, De Rienzo A, Bueno R. The molecular basis of malignant pleural mesothelioma. Thorac Surg Clin 2020; 30: 383–93. doi: 10.1016/j.thorsurg.2020.08.005WadowskiBDe RienzoABuenoRThe molecular basis of malignant pleural mesothelioma2020303839310.1016/j.thorsurg.2020.08.005Open DOISearch in Google Scholar
Berry TA, Belluso E, Vigliaturo R, Gieré R, Emmett EA, Testa JR, et al. Asbestos and other hazardous fibrous minerals: potential exposure pathways and associated health risks. Int J Environ Res Public Health 2022; 19: 4031. doi: 10.3390/ijerph19074031BerryTABellusoEVigliaturoRGieréREmmettEATestaJRAsbestos and other hazardous fibrous minerals: potential exposure pathways and associated health risks202219403110.3390/ijerph19074031Open DOISearch in Google Scholar
Pouliquen DL, Kopecka J. Malignant mesothelioma. Cancers 2021; 13: 3447. doi: 10.3390/cancers13143447PouliquenDLKopeckaJMalignant mesothelioma202113344710.3390/cancers13143447Open DOISearch in Google Scholar
Zhu W, Liu J, Li Y, Shi Z, Wei S. Global, regional, and national trends in mesothelioma burden from 1990 to 2019 and the predictions for the next two decades. SSM Popul Health 2023; 23: 101441. doi: 10.1016/j.ssmph.2023.101441ZhuWLiuJLiYShiZWeiSGlobal, regional, and national trends in mesothelioma burden from 1990 to 2019 and the predictions for the next two decades20232310144110.1016/j.ssmph.2023.101441Open DOISearch in Google Scholar
Cancer in Slovenia 2018. Annual report. Zadnik V, Gašljević G, Hočevar M, Jarm K, Pompe-Kirn V, Strojan P, et al, editors. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Slovenian Cancer Registry; 2020.Annual report.ZadnikVGašljevićGHočevarMJarmKPompe-KirnVStrojanPeditors.LjubljanaInstitute of Oncology Ljubljana, Epidemiology and Cancer Registry, Slovenian Cancer Registry2020Search in Google Scholar
Štrbac, D, Dolžan V. Novel and future treatment options in mesothelioma: a systematic review. Int J Mo Sci 2022; 23: 1975. doi: 10.3390/ijms23041975ŠtrbacDDolžanVNovel and future treatment options in mesothelioma: a systematic review202223197510.3390/ijms23041975Open DOISearch in Google Scholar
Guo X, Lin L, Zhu J. Immunotherapy vs. chemotherapy in subsequent treatment of malignant pleural mesothelioma: which is better? J Clin Med 2023; 12: 2531. doi:10.3390/jcm12072531GuoXLinLZhuJImmunotherapy vs. chemotherapy in subsequent treatment of malignant pleural mesothelioma: which is better?202312253110.3390/jcm12072531Open DOISearch in Google Scholar
Okamoto K, Seimiya H. Revisiting telomere shortening in cancer. Cells 2019; 8: 107. doi: 10.3390/cells8020107OkamotoKSeimiyaHRevisiting telomere shortening in cancer2019810710.3390/cells8020107Open DOISearch in Google Scholar
Razgonova MP, Zakharenko AM, Golokhvast KS, Thanasoula M, Sarandi E, Nikolouzakis K, et al. Telomerase and telomeres in aging theory and chronographic aging theory (review). Mol Med Rep 2020; 22: 1679–94. doi: 10.3892/mmr.2020.11274RazgonovaMPZakharenkoAMGolokhvastKSThanasoulaMSarandiENikolouzakisKTelomerase and telomeres in aging theory and chronographic aging theory (review)20202216799410.3892/mmr.2020.11274Open DOISearch in Google Scholar
Rampazzo E, Cecchin E, Del Bianco P, Menin C, Spolverato G, Giunco S, et al. Genetic variants of the TERT gene. telomere length, and circulating TERT as prognostic markers in rectal cancer patients. Cancers 2020; 12: 3115. doi: 10.3390/cancers12113115RampazzoECecchinEDel BiancoPMeninCSpolveratoGGiuncoSGenetic variants of the TERT gene. telomere length, and circulating TERT as prognostic markers in rectal cancer patients202012311510.3390/cancers12113115Open DOISearch in Google Scholar
Yuan X, Dai M, Xu D. Telomere-related markers for cancer. Curr Top Med Chem 2020; 20: 410–32. doi: 10.2174/1568026620666200106145340YuanXDaiMXuDTelomere-related markers for cancer2020204103210.2174/1568026620666200106145340Open DOISearch in Google Scholar
Levstek T, Redenšek S, Trošt M, Dolžan V, Trebušak Podkrajšek K. Assessment of the telomere length and its effect on the symptomatology of parkinson’s disease. Antioxidants 2021; 10: 137. doi: 10.3390/antiox10010137LevstekTRedenšekSTroštMDolžanVTrebušak PodkrajšekKAssessment of the telomere length and its effect on the symptomatology of parkinson’s disease20211013710.3390/antiox10010137Open DOISearch in Google Scholar
Borges G, Criqui M, Harrington L. Tieing together loose ends: telomere instability in cancer and aging. Mol Oncol 2022; 16: 3380–96. doi: 10.3390/antiox10010137BorgesGCriquiMHarringtonLTieing together loose ends: telomere instability in cancer and aging20221633809610.3390/antiox10010137Open DOISearch in Google Scholar
Cigan SS, Meredith JJ, Kelley AC, Yang T, Langer EK, Hooten AJ, et al. Predicted leukocyte telomere length and risk of germ cell tumours. Br J Cancer 2022; 127: 301–12. doi: 10.1038/s41416-022-01798-3CiganSSMeredithJJKelleyACYangTLangerEKHootenAJPredicted leukocyte telomere length and risk of germ cell tumours20221273011210.1038/s41416-022-01798-3Open DOISearch in Google Scholar
Au AY, Hackl T, Yeager TR, Cohen SB, Pass HI, Harris CC, et al. Telomerase activity in pleural malignant mesotheliomas. Lung Cancer 2011; 73: 283–8. doi: 10.1016/j.lungcan.2010.12.023AuAYHacklTYeagerTRCohenSBPassHIHarrisCCTelomerase activity in pleural malignant mesotheliomas201173283810.1016/j.lungcan.2010.12.023Open DOISearch in Google Scholar
Aida S, Aida J, Naoi M, Kato M, Tsuura Y, Natsume I, et al. Measurement of telomere length in cells from pleural effusion: asbestos exposure causes telomere shortening in pleural mesothelial cells. Pathol Int 2018; 68: 503–8. doi: 10.1111/pin.12710AidaSAidaJNaoiMKatoMTsuuraYNatsumeIMeasurement of telomere length in cells from pleural effusion: asbestos exposure causes telomere shortening in pleural mesothelial cells201868503810.1111/pin.12710Open DOISearch in Google Scholar
Alfudhili KM, Lynch DA, Laurent F, Ferretti GR, Dunet V, Beigelman-Aubry C. et al. Focal pleural thickening mimicking pleural plaques on chest computed tomography: tips and tricks. Br J Radiol 2016; 89: 20150792. doi: 10.1259/bjr.20150792AlfudhiliKMLynchDALaurentFFerrettiGRDunetVBeigelman-AubryCFocal pleural thickening mimicking pleural plaques on chest computed tomography: tips and tricks2016892015079210.1259/bjr.20150792Open DOISearch in Google Scholar
Kim Y, Myong JP, Lee JK, Kim JS, Kim YK, Jung SH, et al. CT characteristics of pleural plaques related to occupational or environmental asbestos exposure from South Korean asbestos mines. Korean J Radiol 2015; 16: 1142–52. doi: 10.3348/kjr.2015.16.5.1142KimYMyongJPLeeJKKimJSKimYKJungSHCT characteristics of pleural plaques related to occupational or environmental asbestos exposure from South Korean asbestos mines20151611425210.3348/kjr.2015.16.5.1142Open DOISearch in Google Scholar
Wolff H, Vehmas T, Oksa P, Rantanen J, Vainio H. Asbestos, asbestosis, and cancer, the Helsinki criteria for diagnosis and attribution 2014: recommendations. Scand J Work Environ Health 2015; 41: 5–15. doi: 10.5271/sjweh.3462WolffHVehmasTOksaPRantanenJVainioHAsbestos, asbestosis, and cancer, the Helsinki criteria for diagnosis and attribution 2014: recommendations20154151510.5271/sjweh.3462Open DOISearch in Google Scholar
Chapel DB, Schulte JJ, Husain AN, Krausz T. Application of immunohistochemistry in diagnosis and management of malignant mesothelioma. Transl Lung Cancer Res 2020; 9(Suppl 1): S3–27. doi: 10.21037/tlcr.2019.11.29ChapelDBSchulteJJHusainANKrauszTApplication of immunohistochemistry in diagnosis and management of malignant mesothelioma20209Suppl 1S32710.21037/tlcr.2019.11.29Open DOISearch in Google Scholar
Munkholm-Larsen S, Cao CQ, Yan TD. Malignant peritoneal mesothelioma. World J Gastrointest Surg 2009; 1: 38–48. doi: 10.4240/wjgs.v1.i1.38Munkholm-LarsenSCaoCQYanTDMalignant peritoneal mesothelioma20091384810.4240/wjgs.v1.i1.38Open DOISearch in Google Scholar
Berzenji L, Van Schil PE, Carp L. The eighth TNM classification for malignant pleural mesothelioma. Transl Lung Cancer Res 2018; 7: 543–9. doi: 10.21037/tlcr.2018.07.05BerzenjiLVan SchilPECarpLThe eighth TNM classification for malignant pleural mesothelioma20187543910.21037/tlcr.2018.07.05Open DOISearch in Google Scholar
Franko A, Goricar K, Kovac V, Dodic-Fikfak M, Dolzan V. NLRP3 and CARD8 polymorphisms influence risk for asbestos-related diseases. J Med Biochem 2020; 39: 91–9. doi: 10.2478/jomb-2019-0025FrankoAGoricarKKovacVDodic-FikfakMDolzanVNLRP3 and CARD8 polymorphisms influence risk for asbestos-related diseases20203991910.2478/jomb-2019-0025Open DOISearch in Google Scholar
Klebe S, Leigh J, Henderson DW, Nurminen M. Asbestos. smoking and lung cancer: an update. Int J Environ Res Public Health 2019; 17: 258. doi: 10.3390/ijerph17010258KlebeSLeighJHendersonDWNurminenMAsbestos. smoking and lung cancer: an update20191725810.3390/ijerph17010258Open DOISearch in Google Scholar
Levstek T, Redenšek S, Trošt M, Dolžan V, Trebušak Podkrajšek K. Assessment of the telomere length and its effect on the symptomatology of Parkinson’s disease. Antioxidants 2021; 10: 137. doi: 10.3390/antiox10010137.LevstekTRedenšekSTroštMDolžanVTrebušak PodkrajšekKAssessment of the telomere length and its effect on the symptomatology of Parkinson’s disease20211013710.3390/antiox10010137Open DOISearch in Google Scholar
Lulkiewicz M, Bajsert J, Kopczynski P, Barczak W, Rubis B. Telomere length: how the length makes a difference. Mol Biol Rep 2020; 47: 7181–8. doi: 10.1007/s11033-020-05551-yLulkiewiczMBajsertJKopczynskiPBarczakWRubisBTelomere length: how the length makes a difference2020477181810.1007/s11033-020-05551-yOpen DOISearch in Google Scholar
Havas A, Yin S, Adams PD. The role of aging in cancer. Mol Oncol 2022; 16: 3213–9. doi: 10.1002/1878-0261.13302HavasAYinSAdamsPDThe role of aging in cancer2022163213910.1002/1878-0261.13302Open DOISearch in Google Scholar
Kusamura S, Baratti D, De Simone M, Pasqual EM, Ansaloni L, Marrelli D, et al. Diagnostic and therapeutic pathway in diffuse malignant peritoneal mesothelioma. Cancers 2023; 15: 662. doi: 10.3390/cancers15030662KusamuraSBarattiDDe SimoneMPasqualEMAnsaloniLMarrelliDDiagnostic and therapeutic pathway in diffuse malignant peritoneal mesothelioma20231566210.3390/cancers15030662Open DOISearch in Google Scholar
Zhou M, Jiang B, Xiong M, Zhu X. Association between TERT rs2736098 polymorphisms and cancer risk-a meta-analysis. Front Physiol 2018; 9: 377. doi: 10.3389/fphys.2018.00377ZhouMJiangBXiongMZhuXAssociation between TERT rs2736098 polymorphisms and cancer risk-a meta-analysis2018937710.3389/fphys.2018.00377Open DOISearch in Google Scholar
Wang M, Sun Y. Telomerase reverse transcriptase rs2736098 polymorphism is associated with lung cancer: a meta-analysis. J Int Med Res 2020; 48: 300060520936173. doi: 10.1177/0300060520936173WangMSunYTelomerase reverse transcriptase rs2736098 polymorphism is associated with lung cancer: a meta-analysis20204830006052093617310.1177/0300060520936173Open DOISearch in Google Scholar
Holesova Z, Krasnicanova L, Saade R, Pös O, Budis J, Gazdarica J, et al. Telomere length changes in cancer: insights on carcinogenesis and potential for non-invasive diagnostic strategies. Genes 2023; 14: 715. doi: 10.3390/genes14030715HolesovaZKrasnicanovaLSaadeRPösOBudisJGazdaricaJTelomere length changes in cancer: insights on carcinogenesis and potential for non-invasive diagnostic strategies20231471510.3390/genes14030715Open DOISearch in Google Scholar
Arimura-Omori M, Kiyohara C, Yanagihara T, Yamamoto Y, Ogata-Suetsugu S, Harada E, et al. Association between telomere-related polymorphisms and the risk of IPF and COPD as a precursor lesion of lung cancer: findings from the Fukuoka tobacco-related lung disease (FOLD) registry. Asian Pac J Cancer Prev 2020; 21: 667–73. doi: 10.31557/APJCP.2020.21.3.667Arimura-OmoriMKiyoharaCYanagiharaTYamamotoYOgata-SuetsuguSHaradaEAssociation between telomere-related polymorphisms and the risk of IPF and COPD as a precursor lesion of lung cancer: findings from the Fukuoka tobacco-related lung disease (FOLD) registry2020216677310.31557/APJCP.2020.21.3.667Open DOISearch in Google Scholar
Cornean CI, Catana A, Maniu AA, Do polymorphisms of the TERT, GSTM1, and GSTT1 genes increase laryngeal cancer susceptibility in smokers of Romanian descent? Medicina (Kaunas) 2022; 58: 1106. doi: 10.3390/medicina5808110CorneanCICatanaAManiuAADo polymorphisms of the TERT, GSTM1, and GSTT1 genes increase laryngeal cancer susceptibility in smokers of Romanian descent?202258110610.3390/medicina5808110Open DOISearch in Google Scholar
He G, Song T, Zhang Y, Chen X, W, Chen H, et al. TERT rs10069690 polymorphism and cancers risk: a meta-analysis. Mol Genet Genomic Med 2019; 7: e00903. doi: 10.1002/mgg3.903HeGSongTZhangYChenX WChenHTERT rs10069690 polymorphism and cancers risk: a meta-analysis20197e0090310.1002/mgg3.903Open DOISearch in Google Scholar
Benitez-Buelga C, Sanchez-Barroso L, Gallardo M, Apellániz-Ruiz M, Inglada-Pérez L, Yanowski K, et al. Impact of chemotherapy on telomere length in sporadic and familial breast cancer patients. Breast Cancer Res Treat 2015; 149: 385–94. doi: 10.1007/s10549-014-3246-6Benitez-BuelgaCSanchez-BarrosoLGallardoMApellániz-RuizMInglada-PérezLYanowskiKImpact of chemotherapy on telomere length in sporadic and familial breast cancer patients20151493859410.1007/s10549-014-3246-6Open DOISearch in Google Scholar
Zins K, Peka E, Miedl H, Ecker S, Abraham D, Schreiber M. Association of the telomerase reverse transcriptase rs10069690 polymorphism with the risk, age at onset and prognosis of triple negative breast cancer. Int J Mol Sci 2023; 24: 1825. doi: 10.3390/ijms24031825ZinsKPekaEMiedlHEckerSAbrahamDSchreiberMAssociation of the telomerase reverse transcriptase rs10069690 polymorphism with the risk, age at onset and prognosis of triple negative breast cancer202324182510.3390/ijms24031825Open DOISearch in Google Scholar
Schneider CV, Schneider KM, Teumer A, Rudolph KL, Hartmann D, Rader DJ, et al. Association of telomere length with risk of disease and mortality. JAMA Intern Med 2022; 182: 291–300. doi: 10.1001/jamainternmed.2021.7804SchneiderCVSchneiderKMTeumerARudolphKLHartmannDRaderDJAssociation of telomere length with risk of disease and mortality202218229130010.1001/jamainternmed.2021.7804Open DOISearch in Google Scholar
Hamada T, Yuan C, Bao Y, Mingfeng Zhang, Natalia Khalaf, Ana Babic, et al. Prediagnostic leukocyte telomere length and pancreatic cancer survival. Cancer Epidemiol Biomarkers Prev 2019; 28: 1868–75. doi: 10.1158/1055-9965.EPI-19-0577HamadaTYuanCBaoYZhangMingfengKhalafNataliaBabicAnaPrediagnostic leukocyte telomere length and pancreatic cancer survival20192818687510.1158/1055-9965.EPI-19-0577Open DOISearch in Google Scholar
Ma R, Liu C, Lu M, Yuan X, Cheng G, Kong F, et al. The TERT locus genotypes of rs2736100-CC/CA and rs2736098-AA predict shorter survival in renal cell carcinoma. Urol Oncol 2019; 37: 301.e1–10. doi: 10.1016/j.urolonc.2019.01.014MaRLiuCLuMYuanXChengGKongFThe TERT locus genotypes of rs2736100-CC/CA and rs2736098-AA predict shorter survival in renal cell carcinoma201937301.e11010.1016/j.urolonc.2019.01.014Open DOISearch in Google Scholar
Pandith AA, Wani ZA, Qasim I, Afroze D, Manzoor U, Amin I, et al. Association of strong risk of hTERT gene polymorphic variants to malignant glioma and its prognostic implications with respect to different histological types and survival of glioma cases. J Gene Med 2020; 22: e3260. doi: 10.1002/jgm.3260PandithAAWaniZAQasimIAfrozeDManzoorUAminIAssociation of strong risk of hTERT gene polymorphic variants to malignant glioma and its prognostic implications with respect to different histological types and survival of glioma cases202022e326010.1002/jgm.3260Open DOISearch in Google Scholar
Nie X, Shang J, Wang W. TERT genetic polymorphism rs2736100 is associated with an aggressive manifestation of papillary thyroid carcinoma. Front Surg 2022; 9: 1019180. doi: 10.3389/fsurg.2022.1019180NieXShangJWangWTERT genetic polymorphism rs2736100 is associated with an aggressive manifestation of papillary thyroid carcinoma20229101918010.3389/fsurg.2022.1019180Open DOISearch in Google Scholar